Overview
- Sanofi announced it will stop the MOBILIZE Phase 3 study of riliprubart in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) who did not respond to standard treatments because the trial is unlikely to meet efficacy goals.
- An independent data monitoring committee reviewed interim results and recommended stopping the study for futility, and Sanofi reported no safety signals tied to riliprubart in that analysis.
- The company said it will work with investigators to wind down the trial and ensure enrolled patients are transitioned to appropriate care or follow-up at study sites.
- Sanofi will perform a detailed analysis of MOBILIZE data to inform future research and will evaluate whether to continue other ongoing riliprubart studies, including the VITALIZE Phase 3 trial.
- Riliprubart is an investigational IgG4 monoclonal antibody that targets activated C1s in the classical complement pathway and has not been reviewed or approved by regulators; Sanofi said the MOBILIZE stop will not materially affect its 2026 financial guidance.